Global and United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Insights, Forecast to 2026

DTaP (also DTPa and TDaP) is a combined vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. This is in contrast to whole-cell, inactivated DTP (aka DTwP). The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole cell vaccines, it is considered safer, but it is also more expensive. Recent research suggests that the DTP vaccine is more effective than DTaP in conferring immunity; this is because DTaP's narrower antigen base is less effective against current pathogen strains.

Market Analysis and Insights: Global and United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market
This report focuses on global and United States Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine QYR Global and United States market.
The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.

Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Scope and Market Size
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is segmented into
Immune DTaP Vaccine
Therapy DTaP Vaccine

Segment by Application, the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is segmented into
Adult
Pediatric

Regional and Country-level Analysis
The Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market is analysed and market size information is provided by regions (countries).
The key regions covered in the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape

and Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Share Analysis
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine business, the date to enter into the Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine product introduction, recent developments, etc.
The major vendors covered:
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc

Frequently Asked Questions